Free, Interactive Telephone Education Program Features Myeloma Experts,
Melissa Alsina, M.D. and Kathy A. Daily, R.N.
WHITE PLAINS, N.Y., Oct. 4 /PRNewswire/ -- Myeloma patients can learn about managing side effects during a free telephone education workshop sponsored by The Leukemia & Lymphoma Society, and led by myeloma experts Melissa Alsina, M.D., and Kathy A. Daily, R.N. of the H. Lee Moffitt Cancer & Research Institute.
"Managing Myeloma Side Effects: What you Need to Know," is scheduled for Wednesday, October 10, 2007, 12 noon -- 1:30 p.m. ET. Dr. Alsina, associate professor of medicine, for the bone marrow transplant program, and Kathy A. Daily, transplant nurse specialist, from the H. Lee Moffitt Cancer & Research Institute in Tampa, FL., will discuss diagnosis and treatment options of patients with myeloma, including information on emerging therapies under study. They will also discuss symptom and side effect management, information on the role of clinical trials and drug therapies in the advancement of myeloma treatment, and quality of life issues. A question-and-answer period will follow.
"The more information Myeloma patients have, the better decisions they can make in regard to treatment and side effect management," explains Robin Kornhaber, M.S.W., the Society's senior vice president of patient services. "We encourage patients, caregivers and healthcare providers to participate in this informative program."
This educational program is supported by Celgene and Millennium Pharmaceuticals. Nurses and social workers who participate in the program have an opportunity to earn 1.5 Continuing Education contact hours.
To register, call toll free by phone (866) 992-9950, ext. 304 or toll free by fax (888) 991-9951; email firstname.lastname@example.org (enter "Myeloma" in the subject field) or visit http://www.lls.org/myelomaeducation. Registrants will receive an information packet and toll free dial-in number within 7-10 days of signing up.
Myeloma is a cancer of the plasma cells, a type of white blood cell found in many tissues of the body, but primarily in the bone marrow. In myeloma, a B lymphocyte, the cell that forms plasma cells, becomes malignant. It grows continuously and forms masses of plasma cells, especially in the marrow, destroying normal blood cell production.
Malignant plasma cells produce an abnormal protein called monoclonal immunoglobulin. Immunoglobulins (or antibodies) are an important part of the body's natural defense against infection because they recognize microbes that invade the body and permit then to be removed and destroyed. The onset of myeloma interferes with normal production of antibodies and makes myeloma patients susceptible to infections.
Often the first symptom of myeloma is bone pain caused by the effects of malignant plasma (myeloma) cells in the marrow. Patients may have anemia, tire more easily and feel weak. Fractures may occur as a result of the weakened bones. Recurrent infections may be an early sign of disease.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.
For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by Masters-level professionals who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
|SOURCE The Leukemia & Lymphoma Society|
Copyright©2007 PR Newswire.
All rights reserved